A Phase I Study to Evaluate the Effect of Darunavir/Ritonavir and Lopinavir/Ritonavir on GSK2248761 Pharmacokinetics and to Assess the Effect of GSK2248761 on CYP450 Probe Drugs in Healthy Adult Subjects.

Trial Profile

A Phase I Study to Evaluate the Effect of Darunavir/Ritonavir and Lopinavir/Ritonavir on GSK2248761 Pharmacokinetics and to Assess the Effect of GSK2248761 on CYP450 Probe Drugs in Healthy Adult Subjects.

Completed
Phase of Trial: Phase I

Latest Information Update: 15 Sep 2010

At a glance

  • Drugs Darunavir; Fosdevirine; Lopinavir/ritonavir; Ritonavir
  • Indications HIV infections; HIV-1 infections
  • Focus Pharmacokinetics
  • Sponsors GlaxoSmithKline
  • Most Recent Events

    • 15 Sep 2010 Actual patient number (n=24) reported at the 50th Interscience Conference on Antimicrobial Agents and Chemotherapy.
    • 15 Sep 2010 Results from this trial were presented at 50th Interscience Conference on Antimicrobial Agents and Chemotherapy.
    • 02 Dec 2009 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top